LAVA Therapeutics NV () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

ImmuCell Corp.

LAVA Therapeutics NV

Marker Therapeutics, Inc.

Cognition Therapeutics, Inc.

VistaGen Therapeutics, Inc.

Quince Therapeutics, Inc.

Gain Therapeutics, Inc.

Precision BioSciences, Inc.

Mainz Biomed NV

Viracta Therapeutics, Inc.

CytoMed Therapeutics Ltd.

Why is LAVA Therapeutics NV ?

Poor long term growth as Operating profit has grown by an annual rate 10.50% of over the last 5 years

The company declared very negative results in Mar'25 after flat results in Dec'24

NET SALES(9M) At USD 4.99 MM has Grown at -32.06%
INTEREST(9M) At USD 0.25 MM has Grown at inf%
NET PROFIT(HY) At USD -14.71 MM has Grown at -66.22%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 14.47%, its profits have fallen by -16%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is LAVA Therapeutics NV for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

LAVA Therapeutics NV

14.47%

-0.31

69.61%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.00%

EBIT Growth (5y)

10.50%

EBIT to Interest (avg)

-34.23

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.57

Sales to Capital Employed (avg)

0.22

Tax Ratio

2.78%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

40.07%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.35

EV to EBIT

0.90

EV to EBITDA

0.91

EV to Capital Employed

0.78

EV to Sales

-6.32

PEG Ratio

Dividend Yield

ROCE (Latest)

86.88%

ROE (Latest)

-128.56%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

NET PROFIT(HY)

Higher at USD -14.71 MM

DEBT-EQUITY RATIO (HY)

Lowest at -281.76 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

OPERATING PROFIT(Q)

Highest at USD -4.67 MM

-17What is not working for the Company

NET SALES(9M)

At USD 4.99 MM has Grown at -32.06%

INTEREST(9M)

At USD 0.25 MM has Grown at inf%

NET PROFIT(HY)

At USD -14.71 MM has Grown at -66.22%

OPERATING CASH FLOW(Y)

Lowest at USD -36.18 MM

ROCE(HY)

Lowest at -90.07%

Here's what is working for LAVA Therapeutics NV

Net Profit

Higher at USD -14.71 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -281.76 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Profit

Highest at USD -4.67 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for LAVA Therapeutics NV

Net Profit

At USD -14.71 MM has Grown at -66.22%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

At USD 4.99 MM has Grown at -32.06%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Interest

At USD 0.25 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow

Lowest at USD -36.18 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)